Jessica O’Hara

Imperial College London - Department of Infectious Disease

SCHOLARLY PAPERS

2

DOWNLOADS

1,579

SSRN CITATIONS

0

CROSSREF CITATIONS

0

Scholarly Papers (2)

1.

Safety and Immunogenicity of a Self-Amplifying RNA Vaccine Against COVID-19: COVAC1, a Phase I, Dose-Ranging Trial

Number of pages: 34 Posted: 16 Jun 2021
Imperial College London - Department of Infectious Disease, Imperial College London - Department of Infectious Disease, University College London - MRC Clinical Trials Unit, NIHR UCLH Clinical Research Facility, Imperial College London, NIHR Imperial Clinical Research Facility, University College London - MRC Clinical Trials Unit, Imperial College London - Department of Infectious Disease, Imperial College London - Department of Infectious Disease, Imperial College London, Imperial College London, University College London Hospitals NHS Foundation Trust - Department of Clinical Virology, University College London, Government of the United Kingdom - Chelsea and Westminster Hospital NHS Foundation Trust, Imperial College London, NIHR Imperial Clinical Research Facility, NIHR Imperial Clinical Research Facility, NIHR Imperial Clinical Research Facility, NIHR Imperial Clinical Research Facility, NIHR Imperial Clinical Research Facility, NIHR Imperial Clinical Research Facility, NIHR Imperial Clinical Research Facility, University of Southampton - NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University of Surrey - Surrey Clinical Research Centre, St George’s University London - St George’s Vaccine Institute, Imperial College London - Department of Infectious Disease, Imperial College London - Section of Virology, University College London - MRC Clinical Trials Unit, University College London - MRC Clinical Trials Unit and Imperial College London - Department of Infectious Disease
Downloads 1,535 (23,527)

Abstract:

Loading...

2.

COVAC1 Phase 2a Expanded Safety and Immunogenicity Study of a Self-Amplifying RNA Vaccine Against SARS-CoV-2

Number of pages: 33 Posted: 27 Sep 2022
University College London - MRC Clinical Trials Unit, Imperial College London - Department of Infectious Disease, Imperial College London - Department of Infectious Disease, Imperial College London - Department of Infectious Disease, University College London - MRC Clinical Trials Unit, St George’s University London - St George’s Vaccine Institute, Government of the United Kingdom - Department of HIV/GUM, Government of the United Kingdom - Department of HIV/GUM, NIHR Imperial Clinical Research Facility - NIHR Imperial Biomedical Research Centre, St George’s University London - St George’s Vaccine Institute, University of Southampton - NIHR Southampton Clinical Research Facility and Biomedical Research Centre, Imperial College London - Section of Virology, St George’s University London - St George’s Vaccine Institute, University of Surrey - Surrey Clinical Research Centre, Imperial College London - Department of Infectious Disease, NIHR UCLH Clinical Research Facility, Imperial College London - Department of Infectious Disease, Chelsea and Westminster Hospital NHS FT, Imperial College London - Department of Infectious Disease, NIHR Imperial Clinical Research Facility - NIHR Imperial Biomedical Research Centre, University of Southampton - NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton - NIHR Southampton Biomedical Research Centre, University College London - Comprehensive Biomedical Research Centre, University of Surrey - Surrey Clinical Research Centre, Imperial College London - Department of Infectious Disease, University of Surrey - Surrey Clinical Research Centre, University College London - Comprehensive Biomedical Research Centre, University College London - MRC Clinical Trials Unit, University College London - MRC Clinical Trials Unit and Imperial College London - Department of Infectious Disease
Downloads 44 (765,283)

Abstract:

Loading...

SARS-CoV-2, vaccination, self-amplifying RNA, saRNA, immune response